Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Oxford Spinout Orbit Discovery Launches Peptide-Discovery Platform

By Drug Discovery Trends Editor | January 27, 2016

Orbit Discovery will work on identifying targeted, affordable therapeutic drugs known as peptides. Source: ShutterstockOrbit Discovery – a new spinout from the University of Oxford – has raised seed funding to commercialize  technology which will help to identify targeted, affordable therapeutic drugs known as peptides.

Oxford Sciences Innovation, the £320m investment company established to provide capital and scaling expertise to Oxford spinouts, is the lead investor in the new company. Other investors include the Oxford Technology and Innovations EIS Fund led by George Robinson and the OT(S)EIS fund managed by Oxford Technology management, which has been making science investments around Oxford for 30 years.

Orbit Discovery will establish a screening platform to identify robust peptide drug candidates for both internal industry drug discovery programs and via collaborative research. The technology was developed at Oxford’s Weatherall Institute of Molecular Medicine by Professor Graham Ogg and Professor Terence Rabbitts.

Orbit CEO Alex Batchelor said: ‘Peptides offer several advantages as drugs. They are small enough to be delivered in tablet form, are highly specific and have safe degradation products. Recent synthetic improvements to peptides have opened up the potential for discovery of drugs for more diseases, but the technologies available for screening have not supported these improvements. Our technology directly addresses this need so we will be screening for active peptides in a range of chronic disease areas.’

Peptide drugs have the potential to provide the highly targeted treatments of more expensive biologic drugs but at a lower price. This makes it possible to treat large patient populations affordably, and to treat diseases that traditional biologics can’t address. The Orbit technology provides screening tools that support the discovery of peptides for a wide range of disease types.

The University’s commercialization company Isis Innovation assisted the founders by filing patents, building the business plan and marketing the opportunity.

Isis Innovation managing director Linda Naylor said: ‘Oxford spinout Orbit Discovery will identify molecules for drug development programmes to treat a wide range of patients and conditions.’

Source: University of Oxford 


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE